Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
Iridex (Nasdaq: IRIX) will report fourth quarter and full year 2025 financial results on March 26, 2026 after market close and provide a business update.
Rhea-AI Summary
Iridex (Nasdaq: IRIX) will report fourth quarter and full year 2025 financial results on March 26, 2026 after market close and provide a business update.
Management will host a conference call on March 26, 2026 at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access on the company website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – IRIX
On Mar 13, the first trading day after this news, IRIX closed 2.26% below the previous close.
Data tracked by StockTitan Argus for the Mar 13 session.
Key Figures
- Earnings release date
- March 26, 2026
- Q4 and full-year 2025 results release after market close
- Conference call time PT
- 2:00 p.m. PT
- Start time for management earnings call
- Conference call time ET
- 5:00 p.m. ET
- Start time for management earnings call
- US dial-in
- +1-646-307-1963
- Domestic access number for earnings call
- International dial-in
- +1-800-715-9871
- International access number for earnings call
- Conference ID
- 3693990
- Audio conference access code
Historical Context
-
Planned HQ move aiming for operating cost savings and efficiency.
-
Preliminary 2025 revenue growth, positive cash flow, and positive adjusted EBITDA.
-
Independent study showing safe, effective MicroPulse retreatment for glaucoma.
-
Modeling study supporting MicroPulse vs continuous-wave glaucoma laser profiles.
-
Participation in Sidoti virtual conference to provide company updates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 3693990. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2026 Iridex Corporation. All rights reserved.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.